26 October 2016
AstraZeneca has announced positive results from the Phase III SOLO-2 trial for determining the effectiveness of Lynparza (olaparib) tablets (300mg twice daily) as a monotherapy for the maintenance treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer. The results demonstrate a statistically-significant and clinically-meaningful improvement of progression-free survival (PFS) among patients treated with Lynparza compared to placebo. This may be considered as additional evidence for supporting the potential use of Lynparza in this patient population.
“We are pleased with the robust improvement in progression-free survival demonstrated by Lynparza in the SOLO-2 trial. We will work with regulatory authorities to make Lynparza tablets available as quickly as possible to patients with ovarian cancer. We remain committed to investigating the full potential of Lynparza, both as monotherapy and in combinations, and to identifying all patients who may benefit from this important medicine,” said Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca.
Initial findings reveal that Lynparza tablets’ safety profile was consistent with previous studies. At a forthcoming medical meeting, full results of SOLO-2 will be presented.
Lynparza Phase III SOLO-2 trial reveals substantial progression-free survival benefitlast edit: 2016-11-02T18:05:25+00:00da